Apoptotic Cell-Mimicking Gold Nanocages Loaded with LXR Agonist for Attenuating the Progression of Murine Systemic Lupus Erythematosus.

Nan Xu,Jun Li,Yujie Gao,Nuoya Zhou,Qiuying Ma,Min Wu,Yamin Zhang,Xiaoyan Sun,Jun Xie,Guanxin Shen,Ming Yang,Qiming Tu,Xiaowei Xu,Jintao Zhu,Juan Tao

DOI: https://doi.org/10.1016/j.biomaterials.2019.01.034

IF: 14

2019-01-01

Biomaterials

Abstract:Systemic lupus erythematosus (SLE) constitutes an autoimmune disease characterized by the breakdown of tolerance to self-antigens, sustained production of pathogenic autoantibodies, and damage to multiple organs and tissues. Nanoparticle (NP)-based therapeutics have demonstrated efficacy in attenuating the progression of SLE. However, investigations of nano-drugs that address the crucial initiating factor in the pathogenesis of SLE; e.g., inefficient clearance of apoptotic cells by phagocytes and consequent accumulation of self-antigens, have seldom been reported. Here, an apoptotic cell-mimicking gold nanocage (AuNC)-based nano drug carrier capable of correcting the impaired clearance of apoptotic cells in SLE was rationally designed and generated by conjugating phosphatidylserine (PS) on the surface of liposome-coated AuNCs for liver X receptor (LXR) agonist T0901317 delivery. Notably, PS-lipos-AuNC@T0901317 could efficiently enhance apoptotic cell clearance by elevating the expression of Mer, one of the pivotal phagocytosis-associated receptors on macrophages, resulting in decreased production of anti-dsDNA autoantibodies, reduced inflammatory response, and alleviation of kidney damage in lupus model mice. Additionally, PS-lipos-AuNC could be tracked by photoacoustic imaging for nano drug carrier biodistribution. By addressing the crucial pathogenic factor of SLE, the NP-based delivery system in this study is envisioned to provide a promising strategy to treat this complex and challenging disease.